Prosecution Insights
Last updated: April 19, 2026
Application No. 18/251,964

A FLUORIDE DENTIFRICE CONTAINING AN IODINE COMPONENT

Final Rejection §103
Filed
May 05, 2023
Examiner
WEBB, WALTER E
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Elevate Oral Care LLC
OA Round
2 (Final)
46%
Grant Probability
Moderate
3-4
OA Rounds
3y 0m
To Grant
66%
With Interview

Examiner Intelligence

Grants 46% of resolved cases
46%
Career Allow Rate
454 granted / 977 resolved
-13.5% vs TC avg
Strong +19% interview lift
Without
With
+19.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
60 currently pending
Career history
1037
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
48.3%
+8.3% vs TC avg
§102
18.8%
-21.2% vs TC avg
§112
15.4%
-24.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 977 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicants' arguments, filed 09/04/2025, have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Claim Rejections - 35 USC § 103—New by Amendment The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. 1) Claim(s) 1-3, 5-8, 11, 13-14, 16-25 are rejected under 35 U.S.C. 103 as being unpatentable over Simon et al., (US 4,592,487, cited in IDS) in view of Nordstrom et al., (Caries Research 2010), and further in view of Vazquez et al., (KR-20090116803). Simon et al. teaches, “Dentifrices comprising two components each of which comprises ingredients usually present in toothpastes or toothpowders, one component containing an iodophor as a source of derived iodine . . . “ (Abstract). As a dentifrice, method of use would have included applying the composition to the oral cavity of a human, as per claims 18-19. The reference teaches a specific embodiment of a dentifrice comprising 10% “PVP-I” (polyvinyl pyrrolidone iodine) and 0.76% “Sodium monofluorophosphate” in a single phase: PNG media_image1.png 466 577 media_image1.png Greyscale (see col. 12, claim 16). The 10% I2 suggests 1% iodine provided by the complex, as per claim 3. Calcium pyrophosphate suffices as the abrasive agent. Other suitable sources of fluoride include “sodium fluoride” (col. 1, line 50), as per claims 5 and 8. Other suitable sources of abrasive include “calcium carbonate” (col. 7, lines 64-65), as per claim 13. Simon et al. does not teach a fluoride content greater than 4500 ppm. Nordstrom et al. teaches, “Adolescents using 5000 ppm F toothpaste had significantly lower progression of caries compared to those using 1,450 ppm F toothpaste . . . . This may indicate that 5,000 ppm F toothpaste has a greater impact on individuals who do not use toothpaste regularly or do not brush twice a day. Thus 5,000 ppm F toothpaste appears to be an important vehicle for cries prevention and treatment of adolescents with a high caries risk” (Abstract). It would have been obvious to a person having ordinary skill in the art at the time of applicant’s filing to provide greater than 4500 ppm fluoride in the dentifrice formulations of Simon et al. for the advantage of treating caries in patients who do not use toothpaste regularly or do not brush twice a day, as taught by Nordstrom et al. The combination of Simon et al. and Nordstrom et al. differs from the instant claims insofar as it does no teach wherein the dentifrice is thixotropic. Vasquez et al. teaches oral care implements, i.e. toothbrushes, for enhanced cleaning of the teeth and soft tissues of the oral cavity (Abstract), where the toothbrushes utilize “toothpaste, which is easily dispensed from a tube (having beneficial yield stress and shear peeling) and cleansed after being applied to the toothbrush (with known stringiness). It is made of a viscoelastic material that is sensitive to shear forces that are blocked and is still recovering its composition in the toothbrush, for example ‘stand up’ (known as thixotropic). Common known toothpastes are, for example, cream toothpastes. Preferably, the tooth paste is of a rheological profile that facilitates dissolution and dispersal, and the rheological profile is a shear rate according to brushing in the oral cavity, which facilitates rapid disintegration and mixing with saliva. It has a sensitive reactivity. Typical toothpaste products have a viscosity of 100-1000 Pa.s at low shear rates, but when mixed with saliva in a ratio of 1:1 to 1:4 (toothpaste:salt), the viscosity drops to 0.01-1.0 Pa.s. The improvement of dissolution and dissemination of toothpaste or other active agent 101 in the oral cavity is such that the viscosity rate is reached faster and more consistently during oral care” (see p. 4 of translation, 2nd paragraph). It would have been obvious to a person having ordinary skill in the art at the time of applicant’s filing to provide that the dentifrice of Simon et al. is thixotropic for the advantage of improvement of dissolution and dissemination of the dentifrice in the oral cavity is such that the viscosity rate is reached faster and more consistently during oral care, as taught by Vasquez et al. 2) Claim(s) 9-10 is/are rejected under 35 U.S.C. 103 as being unpatentable over Simon et al., (US 4,592,487, cited in IDS) in view of Nordstrom et al., (Caries Research 2010) and Vazquez et al., (KR-20090116803) as applied to claim 1 above, and further in view of Mourya et al., (Soft Nanoscience, 2016). The combination of Simon et al., Nordstrom et al., and Vazquez et al., which is taught above, differs from claims 9-10 insofar as they do not teach a particles size for their fluoride compounds. Mourya et al. teaches, “The action of sodium fluoride is mainly used in dental preparations for delivering fluoride ion to the tooth enamel for that nano-particle size is required” (Abstract) Sodium fluoride is characterized has having a particle size of 800 to 1000 nm (see Results and Discussion at p. 5). It would have been obvious to a person having ordinary skill in the art at the time of applicant’s filing to use sodium fluoride having a particle size of less than 50 micrometers or less than 20±2 microns, since 800 to 1000 nm is suitable for treating the enamel, as taught by Mourya et al. Response to Arguments Applicant argues that the claims are overcome by the addition of “thixopic” to the instant claims. Applicant posits that the advantage of being thixotropic, i.e., uniformity, flowability, stability/breakability, are not taught by Simon et al. However, the idea or concept of being thixotropic is not a novel one in the dental arts, as evidenced by Vasquez et al., above. It is a property the art values, which enables the dentifrice to “stand up” on the bristles of the tooth brush. The ability of the dentifrice to behave in a non-Newtonian way serves as advantageous for the improvement of dissolution and dissemination of the dentifrice in the oral cavity is such that the viscosity rate is reached faster and more consistently during oral care use. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Any inquiry concerning this communication or earlier communications from the examiner should be directed to WALTER E WEBB whose telephone number is (571)270-3287 and fax number is (571) 270-4287. The examiner can normally be reached from Mon-Fri 7-3:30. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Frederick F. Krass can be reached (571) 272-0580. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Walter E. Webb /WALTER E WEBB/Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

May 05, 2023
Application Filed
Jun 13, 2025
Non-Final Rejection — §103
Sep 04, 2025
Response Filed
Nov 07, 2025
Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12582600
STABLE GEL COMPOSITION HAVING HIGH OIL CONTENT, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12570932
REMOVAL AND PREVENTION OF BIOFILM BY NANOPARTICLE CHEMISTRIES
2y 5m to grant Granted Mar 10, 2026
Patent 12564657
MOULDABLE ARTIFICIAL BONE COMPOSITE MATERIAL AND PREPARATION METHOD THEREOF
2y 5m to grant Granted Mar 03, 2026
Patent 12564544
THICKENED ALKALYZATION COMPONENT FOR OXIDATIVE HAIR LIGHTENING PRODUCT
2y 5m to grant Granted Mar 03, 2026
Patent 12551425
AQUEOUS ZINC ORAL CARE COMPOSITIONS WITH FLUORIDE
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
46%
Grant Probability
66%
With Interview (+19.0%)
3y 0m
Median Time to Grant
Moderate
PTA Risk
Based on 977 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month